Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitiperstat in moderate to severe COPD
NCT05492877Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2022
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 14
01
Overview
A Phase 2 trial of mitiperstat in chronic obstructive pulmonary disease (COPD), sponsored by AstraZeneca. Started Nov 2022; status: completed.
02
Drugs
mitiperstat
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT05492877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05492877.